SARC031: MEK Inhibitor Selumetinib (AZD6244) in Combination With the mTOR Inhibitor Sirolimus for Patients With Malignant Peripheral Nerve Sheath Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03433183 |
|
Recruitment Status :
Completed
First Posted : February 14, 2018
Last Update Posted : December 26, 2023
|
Sponsor:
Sarcoma Alliance for Research through Collaboration
Collaborators:
United States Department of Defense
AstraZeneca
Information provided by (Responsible Party):
Sarcoma Alliance for Research through Collaboration
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | June 22, 2022 |
| Actual Study Completion Date : | October 1, 2023 |